The New INT Agreement.......DDP-IV Inhibitors
"G1+DDP-IV Inhibitors ......Progressing Rapidly through Pre-Clinicals. Perhaps our next partnership is dependant upon those Pre-Clinical Results if some Co. is looking at taking on the Gastrin Based Therapys as a very Large Package Deal.........that would be speculation at this juncture."
The way the G1+DDP-IV Inhibitors are flying through Pe-Clinicals so fast it leads me to believe that they will be a very big part of the New INT Agreement that Novo and Transition are Hammering Out. I'd expect Stringent Performance Guarantees will be required from Novo this time around!
Leer Target for ---TTHI ---us$21---OutPerform
Keep the good work Dr. Cruz........GLA